Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -1.45
- Piotroski Score 3.00
- Grade Outperform
- Symbol (ACHV)
- Company Achieve Life Sciences, Inc.
- Price $4.17
- Changes Percentage (-1.88%)
- Change -$0.08
- Day Low $4.13
- Day High $4.24
- Year High $5.98
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/13/2025
- Fiscal Year End N/A
- Average Stock Price Target $9.50
- High Stock Price Target $11.00
- Low Stock Price Target $8.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.26
- Trailing P/E Ratio -4.22
- Forward P/E Ratio -4.22
- P/E Growth -4.22
- Net Income $-29,815,000
Income Statement
Quarterly
Annual
Latest News of ACHV
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
With 64% ownership of the shares, Achieve Life Sciences, Inc. (NASDAQ:ACHV) is heavily dominated by institutional owners
Analyzing analyst forecasts and ownership structure can provide insights into a company's future performance. Achieve Life Sciences, Inc. (NASDAQ: ACHV) has institutional investors owning 64% of share...
By Yahoo! Finance | 4 months ago
